Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung (clinicaltrials.gov) - Feb 17, 2022 - P1/2 | N=86 | Recruiting | Sponsor: German Cancer Research Center | Not yet recruiting ➔ Recruiting
Checkpoint inhibition • Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • FOLH1 • IL6R
|